Greatest activity against gram-positive organisms, including:
Staphylococcus aureus,
Streptococcus pyogenes.
Classifications⬆⬇
Therapeutic Classification: anti-infectives
Pharmacokinetics⬆⬇
Absorption: Minimal systemic absorption.
Distribution: Remains in the stratum corneum after topical use for prolonged periods of time (72 hr).
Metabolism/Excretion: Metabolized in the skin; removed by desquamation.
Half-Life: 17–36 min.
Time/Action Profile⬆⬇
(anti-infective effect)
ROUTE
ONSET
PEAK
DURATION
Topical‡
unknown
3–5 days
72 hr
‡Resolution of lesions.
Patient/Family Teaching⬆⬇
Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
Instruct patient on correct application procedure, as well as appropriate hygienic measures to prevent spread of impetigo. If a dose is missed, apply as soon as possible unless almost time for next dose. Avoid contact with eyes.
Advise patient to notify health care provider of all Rx, OTC or topical medications, vitamins, or herbal products being taken and to consult health care provider before taking other medications.
Advise patient to immediately notify health care provider if swelling of lips, face, or tongue or wheezing occurs.
Advise patient to stop mupirocin and notify health care provider if local reaction (irritation, severe itching, rash) occurs.
Rep: Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected or if breastfeeding. To minimize oral exposure to child, a breast treated with mupirocin should be thoroughly washed prior to breastfeeding.
Pronunciation⬆⬇
myoo-PEER-oh-sin
Code⬆
NDC Code
0093- Teva Pharmaceuticals USA, Inc.
0093-1010- Mupirocin
0093-1010-42- 1 TUBE in 1 CARTON (0093-1010-42) / 22 g in 1 TUBE
